Gut microbiota, a vast ecosystem in the human body, form an interconnected coexisting relationship with the organism. Thanks to the flourishing development of molecular biotechnology, recent gut microbiomics studies have shown that to a large extent, gut microorganisms influence the occurrence and development of tumors. In addition to the direct role of the microorganisms themselves, they also play a significant part in causing changes in the host's inflammatory immune system and metabolic functions, and these changes also have a certain impact on the subsequent antitumor therapy. Due to the importance of gut microorganisms, the value of microecological agents developed on this basis for clinical application in tumor patients is becoming more and more apparent, and these microecological agents may be complementary to future antitumor therapy. In this paper, we demonstrate the role of gut microorganisms on malignant tumors from four aspects, including the status of gut microorganisms, the mechanism of gut microorganism-related tumor development, the impact on antitumor therapy and the biotherapies based on gut microorganisms, and provide new ideas and insights for the development and application of subsequent clinical treatment models.